A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer
Authors
Keywords
-
Journal
INVESTIGATIONAL NEW DRUGS
Volume 31, Issue 1, Pages 85-91
Publisher
Springer Nature
Online
2012-02-24
DOI
10.1007/s10637-012-9802-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Metastatic pancreatic cancer: old drugs, new paradigms
- (2011) Thierry Conroy et al. CURRENT OPINION IN ONCOLOGY
- Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies
- (2011) Maarten J. Deenen et al. INVESTIGATIONAL NEW DRUGS
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)
- (2010) Karen E. Bullock et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205
- (2010) Philip A. Philip et al. JOURNAL OF CLINICAL ONCOLOGY
- The Combination of Multiple Receptor Tyrosine Kinase Inhibitor and Mammalian Target of Rapamycin Inhibitor Overcomes Erlotinib Resistance in Lung Cancer Cell Lines through c-Met Inhibition
- (2010) I. Nakachi et al. MOLECULAR CANCER RESEARCH
- Inhibitors of mTOR
- (2010) H.-J. Klumpen et al. ONCOLOGIST
- Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines
- (2009) Silvia La Monica et al. BIOCHEMICAL PHARMACOLOGY
- Dose Escalation Methods in Phase I Cancer Clinical Trials
- (2009) Christophe Le Tourneau et al. JNCI-Journal of the National Cancer Institute
- Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
- (2008) R Bianco et al. BRITISH JOURNAL OF CANCER
- Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
- (2008) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033
- (2008) Charles D. Blanke et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
- (2008) Brian M. Wolpin et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started